Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
- Conditions
- HIV Infections
- Registration Number
- NCT00001040
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC.
SECONDARY: To investigate the pharmacokinetics and effects on various clinical parameters of the three regimens.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (10)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Stanford Univ Med Ctr
🇺🇸Stanford, California, United States
Univ of Colorado Health Sciences Ctr
🇺🇸Denver, Colorado, United States
Northwestern Univ Med School
🇺🇸Chicago, Illinois, United States
Bellevue Hosp / New York Univ Med Ctr
🇺🇸New York, New York, United States
Univ of Rochester Med Ctr
🇺🇸Rochester, New York, United States
Ohio State Univ Hosp
🇺🇸Columbus, Ohio, United States
Girard Med Ctr
🇺🇸Philadelphia, Pennsylvania, United States
Univ TX Galveston Med Branch
🇺🇸Galveston, Texas, United States
Univ of Washington
🇺🇸Seattle, Washington, United States
Univ of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States